This draft white paper from PointCross Life Sciences Inc. (Foster City, CA) presents the opportunities for biomarker and biologics based therapeutic development using search analytics and data integration of clinical and biomarker data as available in its Xbiom solution
Recent FDA Regulatory and Standards UpdatesTuesday, December 11th, 2018
November 4 – 8, 2018 | KAP Europa | Frankfurt, Germany
PhUSE paper- Ensuring consistency of SEND Datasets with Study Reports using Machine Learning Algorithms
PhUSE CSS March Poster_Ensuring consistency of SEND Datasets with Study Reports using Machine Learning Algorithms
Feb 11 – 16, 2018 | San Francisco, CA | Booth # 732
Feb 22, 2018 | Foster City Community Center | Wind Room
March 4 – 6, 2018 | Silver Spring, MD
Our head of SEND Services and Chief Toxicologist at PointCross Life Sciences collaborated on a whitepaper on how to assess your SEND readiness. To access the full document, please click here. We have also summarized the document below. When we check nonclinical studies in SEND format with our SEND-ASSURE service, we find that there are significant inconsistencies...
Benchmark Your SEND Readiness